Resmed (RMD) Equity Income (2018 - 2026)

Resmed (RMD) has 9 years of Equity Income data on file, last reported at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Income rose 130.42% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at -$2.9 million (up 82.84% YoY), and the FY2025 full-year result was $3.6 million, up 297.19% from the prior year.
• Equity Income for Q1 2026 stood at $1.7 million, up from $306000.0 in the prior quarter.
• Across five years, Equity Income topped out at $13.9 million in Q1 2024 and bottomed at -$18.8 million in Q2 2023.
• The 5-year median for Equity Income is -$2.0 million (2022), against an average of -$2.2 million.
• The widest annual swing landed in 2023, when Equity Income soared 344.31%; it then slumped 742.78% in 2025.
• A 5-year view of Equity Income shows it stood at -$2.8 million in 2022, then surged by 33.19% to -$1.9 million in 2023, then surged by 157.04% to $1.1 million in 2024, then tumbled by 71.59% to $306000.0 in 2025, then surged by 461.44% to $1.7 million in 2026.
• The last three Equity Income figures came in at $1.7 million (Q1 2026), $306000.0 (Q4 2025), and -$6.2 million (Q3 2025), per Business Quant data.

Peer Comparison